Na het lezen van de CC heb ik zin om bij te kopen. Daar gaat het om, rotsvast vertrouwen in de bedrifjsvoering. Het slot van de CC vat het samen:
As we have discussed Arrowhead has a lot going on in all of the following stages: one, platform development and expansion into new extra-hepatic tissues, such as lung, tumor, muscle and other cell types; two, early discovery as evidenced by several COVID-related programs, ARO-JNJ1, 2 and 3 and other undisclosed programs; three early development such as ARO-LUNG2, ARO-HIF2, ARO-ENaC and ARO-HSD; and four, emerging mid to later stage developments such as ARO-AAT, ARO-APOC3, ARO-ANG3, and partner programs JNJ-3989 and AMG 890.
This is a very large pipeline with enormous opportunity for a company of only 200 people that currently only burns between $30 million to $35 million per quarter and has a market cap less than $5 billion. This again speaks to Arrowhead culture of finding a way forward and not allowing bureaucracy, or legacy processes to block innovation.